CN105541834A - 一种2-苯基咪唑并[1,2-a]吡啶类化合物的合成方法 - Google Patents
一种2-苯基咪唑并[1,2-a]吡啶类化合物的合成方法 Download PDFInfo
- Publication number
- CN105541834A CN105541834A CN201510975845.7A CN201510975845A CN105541834A CN 105541834 A CN105541834 A CN 105541834A CN 201510975845 A CN201510975845 A CN 201510975845A CN 105541834 A CN105541834 A CN 105541834A
- Authority
- CN
- China
- Prior art keywords
- arh
- synthetic method
- reaction
- pyridine
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010189 synthetic method Methods 0.000 title claims abstract description 20
- KDHWCFCNNGUJCP-UHFFFAOYSA-N 2-phenylimidazo[1,2-a]pyridine Chemical class N1=C2C=CC=CN2C=C1C1=CC=CC=C1 KDHWCFCNNGUJCP-UHFFFAOYSA-N 0.000 title abstract 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 35
- 230000035484 reaction time Effects 0.000 claims abstract description 6
- 230000010355 oscillation Effects 0.000 claims abstract description 5
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical class C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 claims description 35
- ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 2-phenyl-1h-imidazole Chemical compound C1=CNC(C=2C=CC=CC=2)=N1 ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 0.000 claims description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 10
- 238000000498 ball milling Methods 0.000 claims description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 239000006227 byproduct Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000003534 oscillatory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 125000006575 electron-withdrawing group Chemical group 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 4
- 238000000227 grinding Methods 0.000 abstract description 2
- 239000013043 chemical agent Substances 0.000 abstract 1
- 231100000086 high toxicity Toxicity 0.000 abstract 1
- 238000005580 one pot reaction Methods 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 24
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 12
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 12
- VSLIUWLPFRVCDL-UHFFFAOYSA-N zolimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 VSLIUWLPFRVCDL-UHFFFAOYSA-N 0.000 description 7
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- GKQOGAMWHPUXJM-UHFFFAOYSA-N 2-(2-bromophenyl)imidazo[1,2-a]pyridine Chemical compound BrC1=CC=CC=C1C1=CN(C=CC=C2)C2=N1 GKQOGAMWHPUXJM-UHFFFAOYSA-N 0.000 description 3
- SPUPFENARGKGHC-UHFFFAOYSA-N 2-(3-nitrophenyl)imidazo[1,2-a]pyridine Chemical compound [O-][N+](=O)C1=CC=CC(C=2N=C3C=CC=CN3C=2)=C1 SPUPFENARGKGHC-UHFFFAOYSA-N 0.000 description 3
- GRZUOGFRIHABDK-UHFFFAOYSA-N 2-(4-bromophenyl)imidazo[1,2-a]pyridine Chemical compound C1=CC(Br)=CC=C1C1=CN(C=CC=C2)C2=N1 GRZUOGFRIHABDK-UHFFFAOYSA-N 0.000 description 3
- SNBCSKCONKUZBA-UHFFFAOYSA-N 2-(4-nitrophenyl)imidazo[1,2-a]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CN(C=CC=C2)C2=N1 SNBCSKCONKUZBA-UHFFFAOYSA-N 0.000 description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 102000027484 GABAA receptors Human genes 0.000 description 2
- 108091008681 GABAA receptors Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- 150000004941 2-phenylimidazoles Chemical class 0.000 description 1
- 238000010499 C–H functionalization reaction Methods 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- QUDMHFVRKBVGBY-FQEVSTJZSA-N [5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC(=C(N12)CO)N=C1C=CC=C2N1CCN(C)CC1 QUDMHFVRKBVGBY-FQEVSTJZSA-N 0.000 description 1
- JRTIDHTUMYMPRU-UHFFFAOYSA-N alpidem Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N(CCC)CCC)=C1C1=CC=C(Cl)C=C1 JRTIDHTUMYMPRU-UHFFFAOYSA-N 0.000 description 1
- 229950008673 alpidem Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- -1 antituberculosis Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 229950006616 miroprofen Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 1
- 229950005421 olprinone Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960003118 zolimidine Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510975845.7A CN105541834B (zh) | 2015-12-22 | 2015-12-22 | 一种2‑苯基咪唑并[1,2‑a]吡啶类化合物的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510975845.7A CN105541834B (zh) | 2015-12-22 | 2015-12-22 | 一种2‑苯基咪唑并[1,2‑a]吡啶类化合物的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105541834A true CN105541834A (zh) | 2016-05-04 |
CN105541834B CN105541834B (zh) | 2017-08-25 |
Family
ID=55821442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510975845.7A Expired - Fee Related CN105541834B (zh) | 2015-12-22 | 2015-12-22 | 一种2‑苯基咪唑并[1,2‑a]吡啶类化合物的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105541834B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106946875A (zh) * | 2017-02-16 | 2017-07-14 | 杭州师范大学 | 一种c‑3位氧取代的咪唑杂环化合物的制备方法 |
CN108794392A (zh) * | 2018-05-14 | 2018-11-13 | 中国药科大学 | 一种固态球磨合成索拉非尼的方法 |
CN113620919A (zh) * | 2021-06-18 | 2021-11-09 | 浙江工业大学 | 一种2-氨基-3-氰基-4h-吡喃类化合物的机械球磨辅助合成方法 |
CN113651787A (zh) * | 2021-07-28 | 2021-11-16 | 浙江工业大学 | 一种吡喃-2-酮类化合物的无溶剂球磨-氨基酸耦合合成法 |
-
2015
- 2015-12-22 CN CN201510975845.7A patent/CN105541834B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
KASIVISWANADHARAJU PERICHERLA ETAL: "Copper catalyzed tandem oxidative C–H amination/ cyclizations: Direct access to imidazo[1,2-a]pyridines3", 《RSC ADVANCES》 * |
江云兵: "1,2,3-三唑化合物的高效、绿色合成研究", 《中国优秀硕士学位论文全文数据库(工程科技I辑)》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106946875A (zh) * | 2017-02-16 | 2017-07-14 | 杭州师范大学 | 一种c‑3位氧取代的咪唑杂环化合物的制备方法 |
CN106946875B (zh) * | 2017-02-16 | 2019-05-17 | 杭州师范大学 | 一种c-3位氧取代的咪唑杂环化合物的制备方法 |
CN108794392A (zh) * | 2018-05-14 | 2018-11-13 | 中国药科大学 | 一种固态球磨合成索拉非尼的方法 |
CN108794392B (zh) * | 2018-05-14 | 2021-08-10 | 中国药科大学 | 一种固态球磨合成索拉非尼的方法 |
CN113620919A (zh) * | 2021-06-18 | 2021-11-09 | 浙江工业大学 | 一种2-氨基-3-氰基-4h-吡喃类化合物的机械球磨辅助合成方法 |
CN113620919B (zh) * | 2021-06-18 | 2023-12-12 | 浙江工业大学 | 一种2-氨基-3-氰基-4h-吡喃类化合物的机械球磨辅助合成方法 |
CN113651787A (zh) * | 2021-07-28 | 2021-11-16 | 浙江工业大学 | 一种吡喃-2-酮类化合物的无溶剂球磨-氨基酸耦合合成法 |
CN113651787B (zh) * | 2021-07-28 | 2023-11-03 | 浙江工业大学 | 一种吡喃-2-酮类化合物的无溶剂球磨-氨基酸耦合合成法 |
Also Published As
Publication number | Publication date |
---|---|
CN105541834B (zh) | 2017-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105541834A (zh) | 一种2-苯基咪唑并[1,2-a]吡啶类化合物的合成方法 | |
CN105801575A (zh) | 一种咪唑并[1,2-a]吡啶的合成方法 | |
Han et al. | Diastereoselective [3+ 2] cycloaddition of 3-ylideneoxindoles with in situ generated CF 2 HCHN 2: syntheses of CF 2 H-containing spirooxindoles | |
Bakthadoss et al. | A novel synthesis of tetra and pentacyclic quinolinopyran tethered pyrazole/coumarin scaffolds via a solid state melt reaction | |
CN111635300A (zh) | 一种以重水为氘源制备氘代安息香的方法 | |
CN102659494A (zh) | 3,3-二取代-2-氧化吲哚类化合物的不对称合成方法 | |
CN105524013B (zh) | 4,5-二取代-2-取代氨基噻唑化合物的制备方法 | |
CN105949118A (zh) | 一种2-芳基喹啉衍生物的制备方法 | |
CN106146447B (zh) | 一种制备4-氨基亚胺香豆素衍生物的方法 | |
CN109053558B (zh) | 一种n-杂环酰胺衍生物的合成方法 | |
CN104610267B (zh) | 无催化条件下高效的合成6-烷基吡唑并[1,5-c]喹唑啉骨架化合物的方法 | |
CN111892532A (zh) | 一种利用微反应装置合成3-Cl丙酰基取代的含N杂环化合物的方法 | |
CN108299426B (zh) | 一种[1,2,4]-三唑并[4,3-a]吡啶类化合物及其合成方法 | |
CN110963981B (zh) | 一类苯并噻唑芳基化合物衍生物及其制备方法 | |
CN107382858B (zh) | 系列1,2,3,4-四氢异喹啉-4-酮化合物及其合成方法与应用 | |
CN110078766A (zh) | 膦酰化苯并咪唑并异喹啉酮类化合物及其制备方法 | |
CN110156710A (zh) | 一种多取代噁唑类化合物的制备方法 | |
CN104876929A (zh) | 一种1,2,3,4-四氢萘啶类化合物的合成方法及应用 | |
CN105237466B (zh) | 一种合成三取代吡啶衍生物的方法 | |
CN107266311A (zh) | 一种利用微流体芯片反应器连续制备α‑酮酸酯的方法 | |
CN104876940B (zh) | 一种芳香折叠体六元环的合成方法 | |
CN109761926B (zh) | 一种β-异恶唑酮/醛的合成方法 | |
CN105837579A (zh) | 一种多取代苯并[4,5]咪唑并[1,2-b]吡唑衍生物的制备方法 | |
García-Ramírez et al. | Synthesis of 1, 3-oxazoles via Van Leusen reaction in a pressure reactor and preliminary studies of cations recognition | |
CN104910090B (zh) | 二氢异噁唑类化合物及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Ze Inventor after: Wang Fangjian Inventor after: Xu Hui Inventor before: Zhang Zeyuan Inventor before: Wang Fangjian Inventor before: Xu Hui |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211025 Address after: 242000 No. 11, Qilin Avenue, Xuancheng high tech Industrial Development Zone, Xuanzhou District, Xuancheng City, Anhui Province Patentee after: Anhui Hongji Boyin Biotechnology Co.,Ltd. Address before: 241000 Beijing Middle Road, Jiujiang District, Wuhu City, Anhui Province Patentee before: ANHUI POLYTECHNIC University |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170825 |
|
CF01 | Termination of patent right due to non-payment of annual fee |